Jajajajajaja
Venga, a ver si baja un pelín más y le metemos algún titulillo extra...
Las CPRX las liquidaré....están en parte baja de canal, y no me convencen....
Hoy estoy moviditoooooooooooooooooo.....qué peligroooooooooooo
ojalá, si en unas semanas se pone a 6$ liquido toda mi posición para entrar más abajo xD.
Me temo que hasta octubre al menos, nada de nada... Habrá que esperar algún repunte repentino si se quiere hacer caja y poco más.
Ojo, la única duda que tengo ahora mismo es si la están manteniendo hasta la liquidación de opciones de este viernes... Porque el volumen de ayer no me lo explico de ninguna de las maneras. Desde luego algún oso se ha hinchado a comprar ayer...
NYMX
Revendidas las compradas hace un momento, a 1.67
yo leí que prometías 8$ para el ASCO, y que si no se cumplía, la diferencia la pagabas de tu bolsillo :))
Pues nada, todos a la caza del "gap fill"
THLD
ATHX, TIG, células
Cuelgo un artículo especialmente recomendable que acaba de salir en SA. Habla de TIG, una OTC que miro de reojo hace meses y que me parece especialmente prometedora en el campo de las células, pero que lamentablemente IB no me deja comprar, porque es chicharro europeo.
No obstante, el artículo es muy recomendable para todos aquellos que sigan las células, y hace un repaso interesante de la hostia de ATHX y otros previos del sector.
OFF TOPIC: TIG
Info suya que he ido recopilando
TiGenix is testing its adipose-derived stem cells (or eASCs) for the treatment of Crohn's fistulas (phase 3 ongoing), early rheumatoid arthritis (phase 2b to start in Q4-2015) and severe sepsis (phase 1b results due in Q2-2015). In terms of valuation, the treatment of Crohn's fistulas alone represents a $2 billion market opportunity in the U.S. and Europe
The first preliminary efficacy results (24 weeks) are now expected to be released in Q3-2015.
The design of this phase 3 trial was discussed with the EMA, which agreed to consider it as a single pivotal trial leading to market authorization in Europe. In similar discussions with the FDA, after the start of the trial, TiGenix agreed on a U.S. development plan (for which it already filed a Special Protocol Assessment) which will require only one confirmatory pivotal phase 3 trial to be performed in the U.S. to obtain market approval there, provided the European trial is a success.
Información de antes de la hostia de ATHX
TiGenix is valued more than 2x less ($115 million) than ATHX, has phase 3 (not 2!) results coming in Q3-2015 in a very promising indication (Crohn's fistula treatment) and is also developing its eASC platform in early RA (phase 2b starting in 2015) and severe sepsis (phase 1b), based on thoroughly studied immunomudulatory properties of its allogeneic adipose-derived stem cells. And of course, it already has demonstrated efficacy results in Crohn's fistulas and some positive signs of efficacy in RA. So really, that would be my bet in stem cell biotechs for 2015.
TiGenix's future mainly depends on the success or failure of the phase 3 trial of Cx601, as other prospects are still in early-stage developments (phase 1/2). Bigger trials may not replicate the good results of smaller ones. Upon very disappointing results, the company's valuation could well be consequently and durably impacted -- as Cx601 represents a significant amount in the company's current valuation, a downside in the range of 75% in the worst case scenario is not unlikely.
Resultados anuales.
17-3-2015
http://finance.yahoo.com/news/tigenix-tigenix-reports-full-2014-060622828.html
Conferencia audio: http://edge.media-server.com/m/p/cetgefb3/lan/en/st/retail
10-7-2014
Junta extraordinaria: financiación:
By virtue of the resolution of the extraordinary shareholders' meeting held on [DATE] 2014, the board of directors has been expressly authorised to increase the registered capital in one or more transactions with a (cumulated) amount equal to the registered capital, being sixteen million forty-seven thousand six hundred sixty-two euro (EUR 16,047,662.00). This authorisation may be renewed in accordance with the relevant legal provisions.
The board of directors can exercise this power for a period of five (5) years as of the publication of the authorisation in the annexes to the Belgian State Gazette.
6.2. The capital increases to which can be decided pursuant to this authorisation, take place in accordance with the modalities to be determined by the board of directors, by means of a contribution in cash or in kind or through conversion of reserves and issuance premiums, with or without issuance of new shares, with or without voting rights. The board of directors can also use this authorisation for the issuance of convertible bonds, subordinated or not subordinated, warrants, bonds to which warrants or other tangible values are connected, or other securities.
Vídeo de la Stemcell meeting on the MESA
https://www.youtube.com/watch?feature=player_embedded&v=3YpVuoDuX9k
3-4-2014
TiGenix : Licenses Exclusive Marketing And Distribution Rights For Chondrocelect To Swedish Orphan Biovitrum
licensed the marketing and distribution of ChondroCelect, the cell-based medicinal product for the repair of cartilage defects of the knee, to the international specialty healthcare company dedicated to rare diseases, Swedish Orphan Biovitrum AB ('Sobi', NASDAQ OMX Stockholm: SOBI).
TiGenix will receive a royalty of 22% of the net sales of ChondroCelect in the first year of the agreement, and 20% of the net sales of ChondroCelect thereafter. There will be no upfront or milestone payments. The agreement will take effect on 1 June 2014, and has a duration of 10 years.
While TiGenix will initially maintain responsibility for manufacturing, logistics and regulatory affairs, the costs of these activities will be borne by Sobi. TiGenix employees currently engaged in the marketing and distribution of hondroCelect are expected to transfer to Sobi, thereby ensuring continuity of know-how.
Cerrado gap 3,81$.
THLD
12.800 cromos en un solo bloque acabo de ver en 3,81
Pero yo quiero que lo cierre en intradiaaaaaaa vamosssss dame ese capricho perraaaaa
THLD
